So we have two shipments of AZ scheduled to arrive this week.
The first is part of our contract to buy 10 million vaccines from AZ. This latest shipment—Liberty Times says 620,000 expected doses—will reportedly arrive tomorrow, on Wednesday 7/7.
The second is another donation from Japan who reportedly will be sending us some AZ product—in this case 1.13 million doses—actually made in Japan. That shipment will reportedly arrive on Thursday 7/8.
It’s awesome that Japan has stepped up again! But here I want to have a closer look at the AZ delivery from our contract. This batch, unlike the previous ones, is coming from the ill-starred factory in Thailand which has been dealing with problems and delays. So I dug a bit further to try to understand what was going on. If you’re interested, read on.
A report from Bloomberg (link below) had this to say about the situation back on June 11:
AstraZeneca’s choice of Thai partner raised questions from the start. Unlike India’s Serum – which was the world’s biggest vaccine maker before the pandemic – and other Asia partners like South Korea’s SK Bioscience Co., Siam Bioscience is new to the vaccine-making business.
The company was founded in 2009 as Thailand’s first domestic bio-pharmaceutical drugmaker by the father of the nation’s current King Maha Vajiralongkorn, to provide cheaper alternatives to imported drugs. It has also made Covid test kits.
It’s set up by the Crown Property Bureau, an agency that managed assets for the palace no matter who sat on the throne. The company had been operating at a loss in the four years leading up to the year of pandemic, when it brought in a net profit of 35.8 million baht ($1.1 million), according to data published by the Department of Business Development.
In February, Thai Prime Minister Prayuth Chan-Ocha said Siam Bioscience does not seek to profit from making the Astra vaccines.
Royal Links
Complicating matters is Thailand’s lese majeste law, which can see jail time of up to 15 years for defaming the royal family. Its sweeping mandate means that little is said publicly about Siam Bioscience, even as concerns over vaccine supplies grow.
In January, Thai officials said that Siam Bioscience would make 200 million doses each year. They haven’t spoken publicly again about the company in detail since.
When former prime-ministerial candidate Thanathorn Juangroongruangkit suggested that Siam Bioscience’s royal ties played a role in its appointment as AstraZeneca’s partner, the high-profile government critic was charged with royal defamation.
Prime Minister Prayuth apologized this week to the public for the delay, blaming “supply and distribution issues” without elaborating. Neither the Thai government nor Siam Bioscience responded to repeated requests for information on what is causing the supply shortfalls.
One Thai healthcare industry veteran, who asked not to be identified for fear of legal repercussions, likened the situation with Siam Bioscience to a bakery that just started making bread.
“They still haven’t perfected their craft,” he said. “None of us really knows their production capacity because they haven’t publicized it and we can’t criticize it. No one is willing to say. They can’t say it, because it’s Siam Bioscience.”
Let’s just say this is not an ideal situation . . .
Source: Bloomberg - Are you a robot?
Guy